Company intelligence / Profile preview

EVŌQ Bio

Salt Lake City, Utah, United Statesevoqtherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EVŌQ Bio has completed a successful pre-IND meeting with the FDA for its inhaled nanoparticle therapeutic (EVQ-218), designed to treat pulmonary infections in cystic fibrosis; the product has shown preclinical efficacy against top resistant pathogens without evident cytotoxicity

Therapeutic areas: Infectious DiseasesEndocrinology
Modalities: NanoparticleBiologic
Industry: Biotech

Partnerships

Cystic Fibrosis Foundation (grant support)

Beyond the preview

Go deeper on EVŌQ Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVŌQ Bio.

Explore the full profile